ArticleTransboundary and emerging diseases2024
Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS-CoV-2 Reinfections in China.
Article in Transboundary and emerging diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to understand the temporal dynamics of SARS-CoV-2 reinfection risk and assess the impact of inactivated vaccination on the occurrence of reinfection. We investigated the reinfection risk of SARS-CoV-2 from November 1, 2022, to February 12, 2023, when China rapidly lifted the zero-COVID policy. The study subjects were those who were first infected during the zero-COVID period between January 1, 2020, and October 31, 2022, in Dalian city, China. Among the 1961 previous infections, 126 (6.4%, 95% CI: 5.4, 7.5) were reinfected. The risk of reinfection increased over time since initial infection. Compared with those who did not receive or received one dose of inactivated vaccine, receiving two or three doses was associated with additional protection against reinfection among individuals who were infected with pre-Omicron more than a year earlier, with the OR ranged from 0.33 (95% CI: 0.03, 1.83) to 0.91 (95% CI: 0.22, 3.27). In contrast, no protective effect from two or three doses of vaccines against reinfection was observed among those who were first infected with Omicron variants within a year. Primary or booster vaccination contributed to limited protection against reinfection or symptomatic reinfection among individuals infected with Omicron SARS-CoV-2 within a year. However, a booster dose after 1 year of natural infection may provide additional protection against reinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.